Electromed, Inc. (ELMD)

Electromed, Inc. reported strong Q1 2026 financial results, with earnings per share of $0.16, surpassing analysts' estimates. Zacks upgraded Electromed to a "Buy" rating, with analysts having a consensus "Buy" rating and a $36.50 price target. Electromed's Board of Directors initiated a stock buyback plan, authorizing the repurchase of up to $5,000,000 in shares. As of November 25, 2025, ELMD's stock price was $27.68, with a six-month rise of 35.89%, but a year-to-date decrease of 27.14% and a one-year decrease of -7.67%.

The provided search results do not contain specific details regarding seasonal fluctuations in the demand for Electromed, Inc.'s airway clearance therapy products. Information is available on the seasonality of Electromed's stock returns, with February having the highest probability of a positive return and May the lowest, but this pertains to stock performance rather than product demand.

Electromed, Inc. specializes in airway clearance therapy products within the Medical Devices industry. Headquartered in New Prague, Minnesota, the company develops, manufactures, markets, and sells products that apply High Frequency Chest Wall Oscillation (HFCWO) therapy. Key products include the SmartVest Airway Clearance System, SmartVest SQL System, SmartVest Clearway System, SmartVest Connect, and single patient use SmartVest and SmartVest Wrap products. Electromed markets its products to physicians, healthcare providers, and directly to patients.

Electromed, Inc. markets its products in the United States to both the home healthcare and institutional markets. The company also sells its products internationally, both directly and through distributors.

Electromed, Inc. generally holds a positive reputation within the financial community, with an average rating of "Strong Buy" and a consensus "Buy" rating from analysts. MarketBeat's evaluation shows Electromed scoring higher than 69% of companies in the medical sector. There is no information available detailing events that have negatively impacted Electromed, Inc.'s brand reputation in the past year.

Electromed, Inc. is owned by a mix of institutional shareholders and insiders. Institutions hold 46.73% of shares, with major holders including The Vanguard Group, Inc. and BlackRock, Inc. Insiders own 102.28% of the stock, with Red Oak Partners LLC being the largest individual shareholder. Electromed insiders have sold more company stock than they have bought in the past three months.